AU2003271418B2 - Method and apparatus for measuring trends in tissue perfusion - Google Patents
Method and apparatus for measuring trends in tissue perfusion Download PDFInfo
- Publication number
- AU2003271418B2 AU2003271418B2 AU2003271418A AU2003271418A AU2003271418B2 AU 2003271418 B2 AU2003271418 B2 AU 2003271418B2 AU 2003271418 A AU2003271418 A AU 2003271418A AU 2003271418 A AU2003271418 A AU 2003271418A AU 2003271418 B2 AU2003271418 B2 AU 2003271418B2
- Authority
- AU
- Australia
- Prior art keywords
- perfusion
- tpi
- tissue
- signal
- monitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000010412 perfusion Effects 0.000 title claims description 43
- 238000000034 method Methods 0.000 title claims description 11
- 239000000523 sample Substances 0.000 claims description 43
- 238000012544 monitoring process Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000008336 microcirculatory blood flow Effects 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 210000001835 viscera Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 description 72
- 230000004089 microcirculation Effects 0.000 description 26
- 230000017531 blood circulation Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000036770 blood supply Effects 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 210000001715 carotid artery Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 206010040882 skin lesion Diseases 0.000 description 5
- 231100000444 skin lesion Toxicity 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001949 anaesthesia Methods 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000001447 compensatory effect Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000000541 pulsatile effect Effects 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 210000002302 brachial artery Anatomy 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000008822 capillary blood flow Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000011726 slow pulse Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 240000009212 Coccoloba uvifera Species 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010061468 Postoperative wound complication Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229940085371 atenolol 50 mg Drugs 0.000 description 1
- 108091008698 baroreceptors Proteins 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940000032 cardiovascular system drug Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 210000001774 pressoreceptor Anatomy 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Description
0 "Method and apparatus for measuring trends in tissue perfusion" SField of the Invention This invention relates to monitoring and diagnostic apparatus and in particular O to a method and apparatus for measuring tissue perfusion and analysing blood flow C changes as they occur in tissue perfusion.
(N
Background of the Invention 00 The blood circulation is divided into two principal divisions. Firstly, the macrocirculation comprises the heart pump and peripheral arteries and veins for distribution of blood to and from the body tissues. Secondly, the microcirculation is a C' network system of small blood vessels and capillaries. Tissue Perfusion is blood flow Sthrough the microcirculation and tissue perfusion determines the viability of body tissues. Changes in microcirculation occur very early in the train of events leading to evidence of circulatory disturbance.
The microcirculation is an interface system between the terminal ramifications of the arterial and venous compartments of the vascular conduit system, the "Macro circulation". Non-invasive cardiovascular monitoring systems currently in widespread clinical application measure macro parameters such as blood pressure, pulse rate, the Electrocardiogram (ECG) and tissue oxygen saturation (TOS%) which cannot react to early falls in capillary blood flow. While macro parameters provide important feedback to the clinician, they do not reflect the vital activity of the highly sensitive microcirculation.
Figure 1 illustrates the relationship between the skin microcirculation and deeper vasculature. The invention measures by non-invasive means the changes in blood flow in the superficial layer of capillaries, at the very interface between the arterial and venous compartments of vascular system.
The human body has a wide variety of cardiovascular, respiratory and basic reflex mechanisms which endeavour to maintain blood supply to satisfy the metabolic need of the vital organs. Because of the expendability of skin perfusion relative to the vital central organs such as the heart and brain, in the presence of cardiovascular threat, skin microcirculation provides a reserve blood supply by an early compensatory vascoconstrictive mechanism.
Monitoring macro-parameters alone has the following disadvantages. Macroparameters are insensitive to changes in microcirculation prior to compensatory failure, which determine tissue perfusion. By contrast, by monitoring the skin microcirculation, the clinician is able to observe the start of this compensatory activity WO 2004/034895 PCT/AU2003/001379 2 to maintain blood supply to the vital organs, and so therefore gains much earlier warning of any impending threat to physiological status.
The macroparameters do not provide information that is specific to an area of interest (such as the border of a skin lesion or wound). By contrast, assessing the microcirculatory flow of a particular tissue provides direct confirmation that the targeted tissue is receiving nutrients and able to remove waste products. Furthermore, the microcirculatory flow of a targeted area e.g. after trauma or grafting can be compared with anatomical counterpart reference areas of tissue.
US Patent 3,796,214 to F.R.N. Stephens discloses a monitoring system, known as the Stephens Tissue Perfusion Monitor or "STPM", which assesses microcirculatory blood flow in the capillary beds and US Patent 4,442,845 also to F.R.N. Stephens discloses a means of analysing the resulting signal curves. The entire contents of both specifications are incorporated herein by reference.
The STPM's basic parameter, the Tissue Perfusion Index (TPI) is typically derived from the microcirculation of skin or mucous membrane. A non-invasive probe.
provides a source of light and a matched sensor which transduces the variations in reflected light from the capillary bed into an electrical signal (called the signal pulse curve). The TPI is the short term average running product of a value for the area under the pulse curve and an immediate value for pulse rate per minute. As a result, the TPI provides a continuous quantitative measure of proportional changes, as they occur in blood flow through an observed capillary bed of tissue microcirculation, relative to an initial reference level of tissue perfusion.
Ongoing experience with the STPM has shown it invaluable for warning the clinician of subclinical trends in skin tissue perfusion which could threaten patient wellbeing. For example, steadily declining microcirculation from blood loss during surgery causing fall in TPI and no change in TOS, if uncorrected, can precede clinical shock. Unexpected surgical death occurs because of inability to maintain tissue perfusion. In cardiac shock disturbance of skin capillary circulation is observed and continuous surveillance of skin tissue perfusion, with TPI, provides a vital means of identifying trends in response to treatment.
The pathophysiological state of tissue cannot be assessed from macroparameters such as tissue oxygen saturation, pulse rate or blood pressure. This can be readily demonstrated using staged occlusion of the brachial artery with a sphygmomanometer cuff, where it has been reproducibly observed that up to approximately 90% of capillary bed can close down before significant change occurs in tissue oxygen saturation (refer example data in Figure 11). In clinical application, it can therefore be 00 3
O
O
appreciated that the parameters of tissue oxygen saturation, blood pressure, pulse and SECG, though important, cannot measure the early vital capillary flow trends of tissue perfusion which signal imminent shock. This is ordinarily because of the Sphysiologically necessary, large capillary reserve necessary to meet the wide variations that do ordinarily occur to meet metabolic demand.
00 However, although the STPM and the TPI have been known for many years and zt their advantages and benefits understood by many in the medical profession, widespread use of the STPM and the TPI has not occurred. This may be due to difficulties in using the apparatus and in particular, the need to have the probe of the monitor in contact with the area being monitored which is undesirable from the point of view of infection risks and when monitoring damaged tissue.
The present invention seeks to address to problems of the prior art and provide an improved method and apparatus for measuring tissue perfusion.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.
Summary of the Invention In a broad aspect the present invention is directed to a method and apparatus, using a pulsed light source, for measuring microcirculatory flow of a target tissue without the necessity for direct contact of a probe.
According to a first aspect of the present invention there is provided a tissue perfusion monitor for monitoring tissue perfusion in a body including:a probe, arranged to generate a pulsed source of light for irradiation onto a part of a body and a matched sensor, which transduces variations in the reflected light to an electric signal; and.
a signal processor, which receives the electric signal and compares the signal at a first time when the pulsed light source is on with a second time when the pulsed light is off, the first and second times being almost concurrent, the signal processor including:means for processing the electrical signal to reduce or ameliorate the effect of ambient light in the signal; 00 3A means for digitally sampling the processed signal; ;means for generating a pulse curve from the signal means for calculating a heart rate (HR) from the pulse curve; 00 means for determining a running value A for the area under the pulse curve: and means for calculating a Tissue Perfusion Index (TPI) defined by: 00 TPI= A x HR x k where: A running value for area under signal curve HR value for Heart Rate k physiological constant for specific tissue.
O 10 By comparing the signal obtained at these two points in time significant gains in signal to noise ratio can be obtained. Typically the processor digitally samples the 00 4 signal and analyses it to calculate the Tissue Perfusion Index, as well as other measurements relating to the waveform.
The key advantage of the invention, described in this application, is that by using a pulsed light source and compensating for the background signal or noise due to ambient light; measurement of microcirculatory flow can now be obtained without 00 contact between the probe and the target tissue. This reduces the risk of contact artifact at the areas of microcirculation being analysed. Furthermore, because the probe need no longer contact the target tissue, the use of the apparatus is extended (for example to, chronic ulcers on the extremities, the surface of the retina, the vascular pulp within a tooth or the surface of internal organs, accessed by fiberoptic or endoscopic means).
(Ni Finally it can now provide more exact and simpler targeting of accessible tissue for analysis of tissue perfusion (for example, angiogenesis at the border of skin grafts, burns or comparison of microcirculatory activity in or around various skin lesions).
Typically the apparatus will further include a display and/or warning system which at the user's discretion, displays either individual waveforms or selected combinations of waveforms, or a continuous single waveform with a running trace of the TPI trend. The system may be arranged so that selected characteristics of the waveform shape and/or changes in the TPI can activate an audible alarm when the measurement moves above or below pre-defined limits.
The light may or may not be monochromatic.
In a related aspect the present invention provides a method of measuring microcirculatory blood flow in a body comprising the steps of: using an emitter of emitting pulsed infrared light to irradiate an area of the body for measurement of microcirculatory changes; receiving light reflected from the area at a distance from the area being irradiated by the incident light; processing the electrical signal to reduce or ameliorate the effect of ambient light in the signal and digitally sampling the signal; generating a pulse curve from the signal calculating a heart rate (HR) from the pulse curve; determining a running value A for the area under the pulse curve: and calculating a Tissue Perfusion Index (TPI) defined by: TPI A xHR xk where: A running value for area under signal curve HR value for Heart Rate 00 4A
O
O
c k physiological constant for specific tissue and displaying key signal characteristics of the calculated TPI index.
determining from the reflected light a measure of the changes that correspond with the pulsatile filling and partial emptying of the microcirculation.
00 Brief Description of the Drawings Specific examples of the present invention will now be described, by way of example only, and with reference to the accompanying drawings in which:- "Figure 1 shows the dermal vasculature; by courtesy of Waverly Publishers- Williams Williams Wilkins WO 2004/034895 PCT/AU20031001379 Figure 2 is a graphic illustration of a signal derived from a probe embodying the present invention; Figure 3a is a schematic drawing of a first embodiment of a probe Figure 3b is an enlarged end view of the probe of Figure 3a; Figure 4 is a schematic drawing of a second embodiment of a probe; Figure 5 is a schematic drawing of a third embodiment of a probe; Figure 6 is a schematic drawing of a fourth embodiment of a probe; Figure 7 is a schematic drawing of a fifth embodiment of a probe; Figure 8 is a schematic illustration of signal acquisition steps of a system embodying the present invention; Figure 9 is a schematic illustration of the signal processing steps of a system embodying the present invention; Figure 10 is a graph illustrating emitter and sensor voltages; Figure 11 illustrates sample readings of Tissue Perfusion Index (TPI) compared with Tissue Oxygen saturation (TOS), at skin of forearm and finger, during staged occlusion of the brachial artery with a sphygmomanometer, with a fall of almost in TPI occurring before significant change is TOS; Figure 12 illustrates sample readings from the use of a stand off probe embodying the present invention to check blood supply to the scalp, during staged occlusion of the left and right carotid arteries in turn.
Figure 13 illustrates a TPI display of a patient asleep; Figure 14 illustrates a TPI display of the patient of Figure 13 wakening; and Figure 15 shows a slow pulse curve using a standoff probe targeting scalp skin of a hypertensive subject with Bradycardia on a beta blocker drug (Atenolol).
Figure 16 shows a TPI trend curve illustrating an example of rapid intravenous administration of less than 200ml of normal saline solution.
Detailed Description of Preferred Embodiments Referring to the drawings Figures 3 a and 3b shows a first design of a probe embodying the present invention. The probe 10 comprises a high density, black polyethylene tube 12 which is 7mm in diameter and 105mm long which includes a light emitting and a light sensing element, 14 which as is best seen in Figure 3b is a circular, compounded light emitting and sensing device and is placed at the end of the tube. The element 14 comprises a central emitter 16 and an array of surrounding sensors 18. The emitter emits a pulsed light source. An electrostatically shielded cable 20 transfers the electrical signal from the probe 10 to signal processing electronics. Depending on the WO 2004/034895 PCT/AU2003/001379 6 application, the number of sensors or more than one emitter may be used. For example, in Figure 3B, an alternate probe design may comprise a central sensor with one or more emitters.
The principal of operation of the system of the present invention is as follows.
The absorption of light entering a tissue can be said to follow the Beer-Lambert law of attenuation. Consequently, any backscattered light that reaches the sensors 18 is derived primarily from that region of tissue closest to the sensor.
The time varying signal is generated by absorptance levels of the incident infrared light from the probe which falls on the observed tissue's microcirculation during the filling and partial emptying of the microcirculation with blood at each heart beat. The peak wavelength response of the emitter and sensor are approximately matched and include the isobestic point (805nm) on the absorption curves of oxygenated and deoxygentated blood. Importantly, the extravascular interstitial tissue enmeshing the microcirculation is relatively non-absorbent of light at this wavelength in comparison to the pulsatile blood flow of the capillary bed. This means that the backscattered light changes markedly in response to the pulsatile changes in the microcirculation.
As the microcirculation is filled during systole, light absorption increases and light back-scattered to the probe falls. The system circuitry records this fall in backscattered light as indicative of more red blood cells being present in the observed field and proportionally increases the probe's signal. Conversely, as the microcirculation empties during diastole, absorption decreases (and so backscattered light increases), and the probe signal level falls. Consequently, the degree to which the signal rises and falls is closely related to the pulsatile volume of red blood cells passing through the observed field at any instant. This resulting signal is integrated over each heart beat (corresponding to the area under the pulse curve), and multiplied by the heart rate. These products are then averaged over a pre-determined minimum short running time frame to provide an index of tissue perfusion, (that is, the TPI). Put mathematically: TPI varies as Curve Area X Heart Rate (average) (average) Hence in a given running time frame, TPI varies as Red Cells X Cardiac Cycles Cardiac cycles Minute WO 2004/034895 PCT/AU20031001379 7 TPI varies as Red Cells Minute That is, the TPI varies in proportion to any changes in observed capillary blood flow at any given time.
The TPI may be directly expressed as: TPI f Ax HR x k where: A running value for area under signal curve HR value for Heart Rate k physiological constant for specific tissue Figure 2 illustrates the form of a typical time varying signal derived from capillary bed by a probe. Figure 8 is a schematic diagram which sets out the key functional blocks in the signal acquisition by the system of the present invention.
A pulsed light source is used. The pulsed light source enables data acquisition from a signal relatively free of background artifact ("noise") due to interference from ambient light. This enables tissue to be observed, either from a stand-off position across an air gap (for example, 30mm), or using fibre optic bundles to direct a highly focused light source to the target tissue, or provide highly focused sensors to collect light from specific locations. This ability to observe tissue at a distance greatly expands the monitoring capabilities of the new system compared with the existing system and a number of possible novel uses of the system are set out below.
Figure 9 outlines the key signal processing blocks. The electrical signal from the light sensor undergoes Analog to Digital Conversion and the resulting data stream is then smoothed. Following peak detection of the differentiated data stream by use of an active threshold technique, the times at which maximums and minimums occurred in the data stream are determined. These time points are then used as markers to calculate the heart rate (from the time between two successive minimums) and (ii) the TPI (pulse curve area x HR), during this interval. The resulting data streams are separately buffered, for example, the heart rate buffer acquires six seconds of data, while the TPI buffer acquires three seconds. The TPI is then multiplied by the TPI gain value set either manually or automatically using the current signal level as a reference for subsequent data acquisition. Subsequent TPI values are then compared to this WO 2004/034895 PCT/AU20031001379 8 Reference TPI to reflect change in tissue perfusion from an initial state, or tissue perfusion relative to a different location.
In clinical application, the TPI measures change in microcirculation as it occurs from an initial reference level. For example, if the system is being used to monitor a patient during .general anaesthesia, the base reference would be established with the patient in an early settled state prior to anaesthesia.
As a second example, if the system is used to assess capillary activity in a target tissue, for example, a site of inflammatory or neoplastic tissue in, skin, the reference level would be taken from the adjoining normal skin of the subject comfortably supine.
The shape of the signal curve varies with tissue compliance to flow, as physiological or pathological changes in tissue are encountered and so the time point estimates of TPI signal are also used to calculate other characteristics of the signal curve (for example, the rise time and fall time) which is one characteristic of signal shape. The changes in signal curve shape are expressed as variations in rise time Tr (msec) and fall time Tf (msec). These analysis techniques are described in the Prior Art (refer US Patents 3,796,214 and 4,442,845), the entire contents of which are incorporated herein by reference.
The system is controlled using a Personal Computer interface, not illustrated.
Signal processing and display parameters are controlled using keystrokes and the waveform(s) and signal characteristics are displayed on the computer monitor in real time. These digitised signals may also be optionally logged as a digital file for recording and post-processing.
The PC interface provides a multitude of options of display of the information.
For example, if the system is being used during anaesthesia, a declining TPI can indicate compensatory vasoconstriction of skin from blood loss and warning of impending cardiovascular shock. A declining TPI can also indicate clinically nonevident accumulating tissue oedema (for example, from. excess intravenous saline osmotically compromising the capillary bed). The clinician is alerted to these otherwise unknown important disturbances by an optional on/off alarm system which sounds if the TPI, calculated as a moving average figure, moves beyond a high or low predefined range for a finite time (for example 8 seconds) from an initial reference level. The changes in tissue perfusion of the targeted organs are identified for the clinician long before macro-parameters such as blood pressure, heart rate or tissue oxygen saturation, all late indicators of disturbance, show any change.
Alternatively, the system's display can be configured to capture and display the TPI at various locations of the targeted tissue to monitor its viability (for example, WO 2004/034895 PCT/AU20031001379 9 assessing the return of blood supply to a skin graft or characterising themicrocirculation of a skin lesion, or at the border of a skin lesion).
Figure 4 illustrates a second embodiment of a probe 30 in which two high density polyethylene tubes 32, 34 are located side by side. One tube 32 contains a light emitting device 36 arranged to emit a pulsed light source and the other tube 34 contains a light sensing device 38. An analogous implementation using fibre optic cable could be readily employed to provide much smaller, more flexible probe designs using this approach.
Figure 5 illustrates yet a further probe design in which a light emitter 40 and a light sensor 42 are mounted side by side close to the end of a tubular probe 44, suitable for the observation ofintrauterine and cervical tissue .or for intra-rectal examinations.
Figure 6 illustrates yet a further probe 60 which may be transparent and is approximately 20mm long x 15mm wide x 3.5mm deep and can be used as a multipurpose probe for analysing microcirculation at a point of observation on the skin surface. The back of the probe incorporates marks 62 over the sensor to facilitate alignment. The skin may be marked to enable alignment of the sensor over the targeted area of tissue 64.
Figure 7 illustrates yet a further probe 70 which is mounted on adjustable legs 72 to facilitate placement. The optical elements of the probe may be mounted in a telescopic tube to enable different areas of tissue to be examined, such as a skin lesion 74.
In basic application the previous system described in earlier prior art has been invaluable for detection of autonomic disturbances such as due to lightness of anaesthesia, or for correction at skin level of a trend to preshock and for accurate blood replacement following blood loss. However, the invention described herein incorporating a pulsed light source greatly expands the monitoring capabilities to enable assessments of important tissue viability in previously difficult to access areas.
Such areas may include: observations of damaged tissue in bums units, variations in re-vascularisation of tissue in trauma units and in the field of dermatology or following skin grafting, or in the management of post-operative wound breakdown, assessment of retinal microcirculation by splitting and processing back reflected light from a light beam in a slit lamp optical instrument, assessment of viability of tooth pulp tissue through the enamel of the crown of the tooth, and WO 2004/034895 PCT/AU20031001379 the use of two way fibre optic bundles allows viability in difficult to access organ tissues to be monitored, eg, through a ureter to the pelvis of a transplanted kidney.
The assessment of TPI trend in observed microcirculation can provide characteristic waveforms in the TPI trend display that can be triggered by various central nervous system status changes (for example, in the state of sleep or from transient falls in cerebral blood flow) or autonomic status change (for example, such as from afferent stimuli caused by a distending bladder).
In yet another application, arterial stenoses may be located by observing the changes in the TPI reading of skin during sequential occlusion of each of the arterial supply vessels by direct pressure. In this particular application, the TPI is a diagnostically valuable supplement to other vascular diagnostic methods (e.g.
Ultrasound Doppler systems).
In the field of neurology responses in microcirculation occur from influences such as from sympathetic blockade, reflex sympathy dystrophy and causalgia which by tissue blood flow activity and signal curve analysis can be accurately observed and recorded.
Examples Figure 12 illustrates sample readings from the use of a stand off probe embodying the present invention to check blood supply to the scalp. The point of observation of the skim was over an air gap of over 10mm and under bright fluorescent lighting. The subject's left and right carotid arteries were pressure occluded in turn.
The results clearly show a blood supply problem with the left carotid artery supply because compression of the right carotid at 70 produced an excessive 75% fall in scalp tissue perfusion index and an unpleasant near loss of consciousness for the subject who became quickly aware of a passing out sensation. That compares with a smaller fall in TPI and no subject response when the left carotid artery was compressed When the right carotid artery was released at 80 the TPI returned to normal the base reference TPIlevelbeing 100.
The TPI signal also showed "Entrainment Waves" or "E-Waves" at 90. It is known that certain body systems have their own particular respective oscillatory frequency states. Both the relatively slow respiratory rate and the faster beating heart rate can vary promptly. These characteristic oscillatory frequency states differ widely.
For example, physical exertion, sudden emotional stress, the state of sleep, waking from sleep and postural rearrangements such as raising ones body to a standing position WO 2004/034895 PCT/AU20031001379 11 from a supine position causes transient disturbance to the existing dynamics of blood flow in the body.
Whilst the display of tissue perfusion index in the system of the present invention, clearly shows quantified changes in capillary flow, the trend display can also show wave forms with particular characteristic period changes which appear to result from interaction of multi-factorial influences. These changes are referred to as entrainment wave responses or E-Waves. It has been demonstrated that frequencies lower than heart rate, exist in the cardio vascular system (see Traube Hering and Mayer (Periodic posture stimulation of baroreceptor and local vasomotor reflexes, J.
Biomed. Eng. 1992, Vol. 14, July)). It was found that two frequencies were present, one corresponding to breathing rate of about 4 to 6 seconds and another with a period of about 10 seconds, the latter thought to be due to blood pressure control mechanism.
This 10 second frequency was called the THM wave after its discovers. However, until the apparatus of the present invention was developed, these wave forms have not been readily observable.
Both the THM waves period of about 10 seconds and the shorter respiratory related waves with a period of about 4 to 6 seconds, show clearly when present in the continuous two minute TPI trend trace of the computerised monitor. However, during state of sleep, as shown in the TPI display 99 of Figure 13, E wave forms El of a period of around 20-30 seconds, occur not infrequently. With arousal of the subject, these longer period waveforms spontaneously shortened down to around 10 seconds as shown in Figure 14 at 102. If the subject drifts back to sleep the E-Waves lengthen again as shown at 104. These observations were recorded during a conducted hospital study.
Slope varying E-Waves of around 60 seconds appear to relate to the bladder filling with urine. The mechanism of these happenings is not yet understood. It is possible that bladder stretch reflexes generate afferent automatic stimuli which go to the mid brain and higher hypothalamic centres and result in changes to dynamics of tissue blood flow, The resultant effect of this is long TPI trend E-Waves. The apparatus of the present invention provides a means to observe, record and explore subclinical activities within the micro circulation to which conventional parameters of BP pulse, ECG and tissue oxygen percentage saturation are insensitive.
Figure 15 shows a slow pulse curve using a standoff probe of a. hypertensive subject with Bradycardia approximating 50 BPM on medication of atenolol 50 mg once daily. A pause of about 400 milliseconds occurs prior to the start of each systolic WO 2004/034895 PCT/AU20031001379 12 capillary film mode. The graph shows the shape of the probe signal display before conversion to the TPI.
Figure 16 shows a TPI trend curve 110 illustrating an example of rapid intravenous administration of less than 200ml of normal saline solution in a patient. It has induced E waves E 2 having a 40 to 50 second period seen in the TPI trend curve 110 before any significant change in TPI. This suggests the start of an osmotic disturbance caused by the normal saline solution.
While this application describes one embodiment of the invention, other variations in signal acquisition design to achieve the same capabilities are possible. For example, data may be acquired while the light emitter is switched off, to provide an active sample of background noise, which can then be digitally subtracted from the signal. Band pass filters may be applied to reduce noise outside the relatively low frequencies of concern before data analysis. As noted there is a wide range of probe designs of which several examples are disclosed.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
Claims (8)
- 2. A perfusion monitor for monitoring tissue perfusion in a body as claimed in claim 1 wherein the probe is arranged to generate a pulsed source of infrared light.
- 3. A perfusion monitor for monitoring tissue perfusion in a body as claimed in claim 1 or 2 further including a display and/or warning system which at the user's discretion, displays either individual waveforms or selected combinations of waveforms, or a continuous single waveform with a running trace of the TPI trend.
- 4. A perfusion monitor for monitoring tissue perfusion in a body as claimed in claim 3 wherein the warning system is arranged so that selected characteristics of the waveform shape and/or changes in the TPI activate an audible alarm when the measurement moves above or below pre-defined limits.
- 5. A perfusion monitor for monitoring tissue perfusion in a body as claimed in any preceding claim wherein the light generated by the pulsed source is monochromatic. 00 14 O
- 6. A perfusion monitor for monitoring tissue perfusion in a body as claimed in any o preceding claim wherein the probe includes two fibre optic cable tubes disposed side by side through one of which the pulsed light source is transmitted and through the other of which the reflected light is received. 00
- 7. A method of measuring microcirculatory blood flow in a body comprising the steps of: emitting pulsed infrared light to irradiate an area of the body for measurement of microcirculatory changes; ~receiving light reflected from the area at a distance from the area being irradiated by the incident light; processing the electrical signal to reduce or ameliorate the effect of ambient light in the signal digitally sampling the signal; generating a pulse curve from the signal calculating a heart rate (HR) from the pulse curve; determining a running value A for the area under the pulse curve: and calculating a Tissue Pe TPI= A x HR x k where: A running value for area under signal curve HR value for Heart Rate k physiological constant for specific tissue and displaying key signal characteristics of the calculated TPI index.
- 8. The use of the perfusion monitor of any one of claims 1 to 8 to monitor perfusion in chronic ulcers on the extremities, the surface of the retina, the vascular pulp within a tooth or the surface of internal organs.
- 9. The use of the method of any one of claims 9 to 1 I to monitor perfusion in chronic ulcers on the extremities, the surface of the retina, the vascular pulp within a tooth or the surface of internal organs. The use of the tissue perfusion monitor of any one of claims 1 to 6 to detect and display a subject's Entrainment waves. 00 N ~11. The use of the method of claim 7to detect anddisplay asubject's Entrainment waves. 0
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003271418A AU2003271418C1 (en) | 2002-10-17 | 2003-10-17 | Method and apparatus for measuring trends in tissue perfusion |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002952144 | 2002-10-17 | ||
| AU2002952144A AU2002952144A0 (en) | 2002-10-17 | 2002-10-17 | Method and apparatus for measuring tissue perfusion |
| PCT/AU2003/001379 WO2004034895A1 (en) | 2002-10-17 | 2003-10-17 | Method and apparatus for measuring tissue perfusion |
| AU2003271418A AU2003271418C1 (en) | 2002-10-17 | 2003-10-17 | Method and apparatus for measuring trends in tissue perfusion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2003271418A1 AU2003271418A1 (en) | 2004-05-04 |
| AU2003271418B2 true AU2003271418B2 (en) | 2008-11-06 |
| AU2003271418C1 AU2003271418C1 (en) | 2009-04-02 |
Family
ID=34314427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003271418A Ceased AU2003271418C1 (en) | 2002-10-17 | 2003-10-17 | Method and apparatus for measuring trends in tissue perfusion |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2003271418C1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3796213A (en) * | 1970-09-18 | 1974-03-12 | F Stephens | Perfusion monitor |
| US5318022A (en) * | 1991-03-01 | 1994-06-07 | John Taboada | Method and apparatus for determining hemoglobin oxygenation such as in ocular and other vascular beds |
| US5846190A (en) * | 1995-10-10 | 1998-12-08 | Hewlett-Packard Company | Method of and apparatus for recognizing falsified pulse oximetry measurements |
| US5995859A (en) * | 1994-02-14 | 1999-11-30 | Nihon Kohden Corporation | Method and apparatus for accurately measuring the saturated oxygen in arterial blood by substantially eliminating noise from the measurement signal |
| US5995856A (en) * | 1995-11-22 | 1999-11-30 | Nellcor, Incorporated | Non-contact optical monitoring of physiological parameters |
| US6083158A (en) * | 1998-09-01 | 2000-07-04 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Real-time visualization of tissue ischemia |
| JP2001046348A (en) * | 1999-08-10 | 2001-02-20 | Omega Wave Kk | Probe for blood flow meter |
-
2003
- 2003-10-17 AU AU2003271418A patent/AU2003271418C1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3796213A (en) * | 1970-09-18 | 1974-03-12 | F Stephens | Perfusion monitor |
| US5318022A (en) * | 1991-03-01 | 1994-06-07 | John Taboada | Method and apparatus for determining hemoglobin oxygenation such as in ocular and other vascular beds |
| US5995859A (en) * | 1994-02-14 | 1999-11-30 | Nihon Kohden Corporation | Method and apparatus for accurately measuring the saturated oxygen in arterial blood by substantially eliminating noise from the measurement signal |
| US5846190A (en) * | 1995-10-10 | 1998-12-08 | Hewlett-Packard Company | Method of and apparatus for recognizing falsified pulse oximetry measurements |
| US5995856A (en) * | 1995-11-22 | 1999-11-30 | Nellcor, Incorporated | Non-contact optical monitoring of physiological parameters |
| US6083158A (en) * | 1998-09-01 | 2000-07-04 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Real-time visualization of tissue ischemia |
| JP2001046348A (en) * | 1999-08-10 | 2001-02-20 | Omega Wave Kk | Probe for blood flow meter |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003271418C1 (en) | 2009-04-02 |
| AU2003271418A1 (en) | 2004-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Csipo et al. | Assessment of age-related decline of neurovascular coupling responses by functional near-infrared spectroscopy (fNIRS) in humans | |
| Lindberg et al. | Monitoring of respiratory and heart rates using a fibre-optic sensor | |
| KR100512290B1 (en) | Method and apparatus for the non-invasive detection of medical conditions by monitoring peripheral arterial tone | |
| JP5645655B2 (en) | Noninvasive measurement of blood oxygen saturation | |
| US20060149154A1 (en) | Method and apparatus for measuring tissue perfusion | |
| EP1601287B1 (en) | Assessment of a decrease in blood volume using cardiovascular waveforms | |
| KR100660349B1 (en) | Mobile blood pressure monitoring device using optical blood flow measurement signal | |
| JP4031438B2 (en) | Biological function diagnostic device | |
| US7570979B2 (en) | Methods and apparatus for patient monitoring | |
| KR100519758B1 (en) | Method and apparatus for evaluating human stress using PPG | |
| CA2564059C (en) | System for measuring pulsatile vascular resistance | |
| Kowalchuk et al. | The effect of resistive breathing on leg muscle oxygenation using near-infrared spectroscopy during exercise in men | |
| CA3097663A1 (en) | Methods to estimate the blood pressure and the arterial stiffness based on photoplethysmographic (ppg) signals | |
| JP2003511101A (en) | Apparatus and method for continuous non-invasive determination of physiological properties | |
| Zahedi et al. | Finger photoplethysmogram pulse amplitude changes induced by flow-mediated dilation | |
| NZ524765A (en) | Non-invasive measurement of suprasystolic signals | |
| Lopez-Beltran et al. | Non-invasive studies of peripheral vascular compliance using a non-occluding photoplethysmographic method | |
| Schultz-Ehrenburg et al. | Value of quantitative photoplethysmography for functional vascular diagnostics: current status and prospects | |
| US10004438B2 (en) | Implantable real-time oximeter to determine potential strokes and post-traumatic brain-injury complications | |
| Mashayekhi et al. | Flow mediated dilation with photoplethysmography as a substitute for ultrasonic imaging | |
| Kamshilin et al. | Imaging photoplethysmography and its applications | |
| AU2003271418B2 (en) | Method and apparatus for measuring trends in tissue perfusion | |
| Anisimov et al. | Comparison of heart rate derived from ECG and pulse wave signals during controlled breathing test for biofeedback systems | |
| Tursky et al. | Measurement of cardiovascular functioning | |
| KR200380928Y1 (en) | Hand-held type blood pressure monitoring system using PPG signal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 NOV 2008. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 NOV 2008 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |